Platelet aggregation by membrane-expressed A1 domains of von Willebrand Factor is dependent on residues Asp 560 and Gly 561

Biochemical and Biophysical Research Communications

Volumn 302, Issue 4, 2003, Pages 873-877

  Schulte Am Esch II, Jan ^a   Robson, Simon C ^b   Cruz, Miguel A ^c,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; RISTOCETIN; VON WILLEBRAND FACTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL STRAIN COS7; GENETIC TRANSFECTION; MODEL; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN VARIANT; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

EID: 0037459149     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00278-X     Document Type: Article

References (18)

1. Schulte am Esch II J., Cruz M.A., Siegel J.B., Anrather J., Robson S.C. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor. Blood. 90:1997;4425-4437.
2. Emsley J., Cruz M.A., Handin R., Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J. Biol. Chem. 273:1998;10396-10401.
3. Pietu G., Meulien P., Cherel G., Diaz J., Baruch D., Courtney M., Meyer D. Production in Escherichia coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. Biochem. Biophys. Res. Commun. 164:1989;1339-1347.
4. Sugimoto M., Ricca G., Hrinda M.E., Schreiber A.B., Searfoss G.H., Bottini E., Ruggeri Z.M. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry. 30:1991;5202-5209.
5. Cruz M.A., Handin R.I., Wise R.J. The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J. Biol. Chem. 268:1993;21238-21245.
6. Cruz M.A., Yuan H., Lee J.R., Wise R.J., Handin R.I. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J. Biol. Chem. 270:1995;10822-10827.
7. Miyata S., Goto S., Federici A.B., Ware J., Ruggeri Z.M. Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibα J. Biol. Chem. 271:1996;9046-9053.
8. Cruz M.A., Diacovo T.G., Emsley J., Liddington R., Handin R.I. Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J. Biol. Chem. 275:2000;19098-19105.
9. Vasudevan S., Roberts J.R., McClintock R.A., Dent J.A., Celikel R., Ware J., Varughese K.I., Ruggeri Z.M. Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibα J. Biol. Chem. 275:2000;12763-12768.
10. Jenkins P.V., Pasi K.J., Perkins S.J. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood. 91:1998;2032-2044.
11. Meyer D., Fressinaud E., Gaucher C., Lavergne J.M., Hilbert L., Ribba A.S., Jorieux S., Mazurier C. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb. Haemost. 78:1997;451-456.
12. Rabinowitz I., Tuley E.A., Mancuso D.J., Randi A.M., Firkin B.G., Howard M.A., Sadler J.E. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc. Natl. Acad. Sci. USA. 89:1992;9846-9849.
13. Mohri H., Fujimura Y., Shima M., Houghten R.A., Ruggeri Z.M., Zimmerman T.S. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J. Biol. Chem. 263:1988;17901-17904.
14. Roberson D.W., Upchurch G.R. Jr., Lamb M.A., Read M.S., Wagner R.H., Cooper H.A. A paradoxical effect of antibody concentration on vWF-dependent platelet agglutination distinguishes between botrocetin and ristocetin-induced agglutination. Thromb. Res. 44:1986;749-760.
15. Girma J.P., Takahashi Y., Yoshioka A., Diaz J., Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb. Haemost. 64:1990;326-332.
16. Hillery C.A., Mancuso D.J., Sadler J.E., Ponder J.W., Jozwiak M.A., Christopherson P.A., Cox G.J., Scott P.J., Montgomery R.R. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristoc. Blood. 91:1998;1572-1581.
17. Dong J.F., Bernt M.C., Schade A., McIntire L.V., Andrews R.K., Lopez J.A. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood. 97:2001;162-168.
18. Huizinga E.G., Tsuji S., Romijn R.A.P., Schiphorst M.E., de Groot P.G., Sixma J.J., Gros P. Structures of glycoprotein Ib. α and its complex with von Willebrand Factor A1 domain Science. 297:2002;1176-1179.